AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23494667 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise implementation intentions
Number of subjects: 40
Study 23494667 — intervention group
Group type: COMPARATOR
Intervention: Social implementation intentions
Number of subjects: 40
Study 23207889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity (75% HRR)
Number of subjects: 45
Study 23207889 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal-intensity intervals (95/50% HRR)
Number of subjects: 45
Study 23207889 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity (50% HRR)
Number of subjects: 45
Study 23207889 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 45
Study 19952807 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity (PA) increase of 100 cpm
Number of subjects: 38
Study 19952807 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity (PA) increase
Number of subjects: 38
Study 19952807 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) changes
Number of subjects: 38
Study 18458896 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 24
Study 16875644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 866
Study 16875644 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen/medroxyprogesterone acetate [0.625/2.5 mg]
Number of subjects: 866
Study 16875644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866
Study 12806567 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM group (n = 43)
Number of subjects: 84
Study 12806567 — intervention group
Group type: COMPARATOR
Intervention: no-TDM group (n = 41)
Number of subjects: 84
Study 11018571 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8928704 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 U/kg)
Number of subjects: 204
Study 8928704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 1510005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of insulin (0.1 U/kg body weight 4 times a day for 7 days)
Number of subjects: 46
Study 1510005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of insulin
Number of subjects: 46
Study 1510005 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 46
Study 1510005 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study 1510005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of insulin (once, n = 6)
Number of subjects: 46
Study 6845776 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 30
Study 29610982 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma
Number of subjects: 38
Study 29610982 — intervention group
Group type: COMPARATOR
Intervention: Duraphat
Number of subjects: 38
Study 29610982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents (Gluma and Duraphat)
Number of subjects: 38
Study 29518123 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive learning tool
Number of subjects: 285
Study 29518123 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-competitive learning)
Number of subjects: 285
Study 27310945 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000mL cold saline with 0.5% epinephrine
Number of subjects: 420
Study 27310945 — intervention group
Group type: COMPARATOR
Intervention: Normal temperature solution
Number of subjects: 420
Study 24731120 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 1193
Study 22776336 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic varicocelectomy
Number of subjects: 153
Study 22776336 — intervention group
Group type: COMPARATOR
Intervention: Open inguinal varicocelectomy
Number of subjects: 153
Study 22776336 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal varicocelectomy
Number of subjects: 153
Study 22776336 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (preoperative vs postoperative semen parameters)
Number of subjects: 153
Study 19671656 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 734
Study 19671656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study 19671656 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 734
Study 17472001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cernilton for 3 months (group 1)
Number of subjects: 93
Study 17472001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cernilton for 3 months + antibacterial treatment for 8 months (group IIa)
Number of subjects: 93
Study 17472001 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic treatment for 2 months maximally (group IIb)
Number of subjects: 93
Study 15642574 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 0
Study 12086555 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (human recombinant interleukin‐1 receptor antagonist)
Number of subjects: 0
Study 12086555 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (monotherapy)
Number of subjects: 0
Study 12086555 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra plus methotrexate (combination therapy)
Number of subjects: 0
Study 12086555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9802741 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 90
Study 9802741 — intervention group
Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 90
Study 7899379 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 900 mg-metoclopramide 10 mg effervescent association (AAM)
Number of subjects: 303
Study 7899379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 2677293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and spironolactone
Number of subjects: 34
Study 2677293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 873714 — intervention group
Group type: EXPERIMENTAL
Intervention: benserazide
Number of subjects: 32
Study 873714 — intervention group
Group type: COMPARATOR
Intervention: chlorpromazine
Number of subjects: 32
Study 30958332 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) injection
Number of subjects: 186
Study 30958332 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 186
Study 28751548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 66
Study 28751548 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 15-30 mg
Number of subjects: 66
Study 23949558 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered care
Number of subjects: 506
Study 23949558 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 506
Study 24501857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (n = 62)
Number of subjects: 103
Study 24501857 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 41)
Number of subjects: 103
Study 19341122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2) with N-acetylcysteine (NAC)
Number of subjects: 50
Study 19341122 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy (HBO2) without N-acetylcysteine (NAC)
Number of subjects: 50
Study 19341122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 50
Study 17597496 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 28
Study 17597496 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 28
Study 15490811 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole 2.5 mg
Number of subjects: 72
Study 15490811 — intervention group
Group type: COMPARATOR
Intervention: anastrozole 1 mg
Number of subjects: 72
Study 11557681 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 90
Study 11557681 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (1 mg 17beta‐estradiol combined with 0.5 mg norethisterone acetate)
Number of subjects: 90
Study 11557681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 9786808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for 10 weeks
Number of subjects: 51
Study 9786808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific antidepressant treatment)
Number of subjects: 51
Study 7973171 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives, enablers, medication monitors, and chemotherapeutic regimens allowing direct administration of medication combined with effective patient-physician relationship
Number of subjects: 0
Study 7973171 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education and medication labeling methods
Number of subjects: 0
Study 3293875 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 19
Study 3293875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 19
Study 3293875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31580705 — intervention group
Group type: EXPERIMENTAL
Intervention: Shi-style cervical mobilizations (SCM)
Number of subjects: 360
Study 31580705 — intervention group
Group type: COMPARATOR
Intervention: Traditional massage (TM)
Number of subjects: 360
Study 31518645 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-DRG model
Number of subjects: 1414
Study 31518645 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-HCT-CR model
Number of subjects: 1414
Study 31518645 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-DRG and AML-HCT-CR models
Number of subjects: 1414
Study 28371900 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC; 2.4 mg/g nicotine or less) cigarettes
Number of subjects: 717
Study 28371900 — intervention group
Group type: COMPARATOR
Intervention: Normal nicotine content (NNC; 15.8 mg/g) cigarettes
Number of subjects: 717
Study 28371900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VLNC and NNC cigarettes
Number of subjects: 717
Study 26601156 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV9-IGHMBP2 administration via systemic injection
Number of subjects: 1
Study 26601156 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV9-IGHMBP2 administration in human SMARD1-induced pluripotent stem cell-derived motor neurons
Number of subjects: 1
Study 23967638 — intervention group
Group type: COMPARATOR
Intervention: Botox group (local injection of botox type A)
Number of subjects: 42
Study 23967638 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (matrix needling technique and acupuncture at Fengchi, 'Wuxin points', and local Ashi points)
Number of subjects: 42
Study 21715011 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 392
Study 21715011 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 392
Study 21715011 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 392
Study 19596010 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (10 mg/d for weight <35 kg; 20 mg/d for weight >35 kg)
Number of subjects: 90
Study 19596010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19596010 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 90
Study 16705580 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic Lactobacillus casei subspecies rhamnosus (6 x 10^9 cfu/day) added to human milk
Number of subjects: 80
Study 16705580 — intervention group
Group type: COMPARATOR
Intervention: Human milk alone
Number of subjects: 80
Study 12648735 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-factor model for PANSS
Number of subjects: 535
Study 12648735 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-factor model for PANSS
Number of subjects: 535
Study 12648735 — intervention group
Group type: EXPERIMENTAL
Intervention: Future studies
Number of subjects: 535
Study 10685484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrel-Dubousset instrumentation
Number of subjects: 67
Study 10685484 — intervention group
Group type: COMPARATOR
Intervention: Colorado instrumentation
Number of subjects: 67
Study 8659761 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine infusion
Number of subjects: 22
Study 8659761 — intervention group
Group type: COMPARATOR
Intervention: Control (no felodipine)
Number of subjects: 22
Study 1531993 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 52
Study 1531993 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 52
Study 3984771 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl withdrawal
Number of subjects: 22
Study 3984771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29343509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tregalizumab 25 mg
Number of subjects: 321
Study 29343509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tregalizumab 100 mg
Number of subjects: 321
Study 29343509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tregalizumab 200 mg
Number of subjects: 321
Study 29343509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 26811968 — intervention group
Group type: EXPERIMENTAL
Intervention: CHoBI7 intervention (hand washing with soap and water treatment)
Number of subjects: 439
Study 26811968 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 439
Study 24980662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 200,000 IU for 2 months followed by 100,000 IU monthly for 18 months
Number of subjects: 322
Study 24980662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 21956241 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 49
Study 21956241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 20179653 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 36
Study 20179653 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MLS)
Number of subjects: 36
Study 17636181 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment course in Tunisia
Number of subjects: 134
Study 17636181 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 134
Study 17636181 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment
Number of subjects: 134
Study 17636181 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study 16042774 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage fluid analysis for SP‐B, SP‐C and their proforms
Number of subjects: 62
Study 12443741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (5 ml of 1% lignocaine)
Number of subjects: 80
Study 12443741 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo (5 ml)
Number of subjects: 80
Study 12443741 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid sinus nerve excision
Number of subjects: 80
Study 12443741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 80
Study 10502216 — intervention group
Group type: EXPERIMENTAL
Intervention: Efegatran sulfate plus streptokinase (1.5 million U)
Number of subjects: 245
Study 10502216 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus accelerated tissue plasminogen activator (TPA)
Number of subjects: 245
Study 8952600 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 82
Study 8952600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 82
Study 1743190 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol (Optiray)
Number of subjects: 743
Study 1743190 — intervention group
Group type: COMPARATOR
Intervention: monomeric nonionic reference product
Number of subjects: 743
Study 7206052 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (600 mg per M², administered intravenously weekly)
Number of subjects: 118
Study 7206052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin and 5-fluorouracil
Number of subjects: 118
Study 30853622 — intervention group
Group type: EXPERIMENTAL
Intervention: Carob supplementation (SG, n = 11)
Number of subjects: 23
Study 30853622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG, n = 12)
Number of subjects: 23
Study 29174928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 29174928 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g IN
Number of subjects: 86
Study 29174928 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g IN
Number of subjects: 86
Study 29174928 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g IN
Number of subjects: 86
Study 26887289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 50
Study 26887289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22815250 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation FlatStent device
Number of subjects: 95
Study 22815250 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation FlatStent EF device
Number of subjects: 95
Study 22815250 — intervention group
Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 95
Study 21557777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional cryosurgery with pain-control protocol (oral pain-relief tablets Dipyrone and translesional local anaesthesia with Bupivacaine hydrochloride 0.5%)
Number of subjects: 29
Study 21557777 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact cryosurgery with pain-control protocol
Number of subjects: 29
Study 21557777 — intervention group
Group type: COMPARATOR
Intervention: Control group (contact cryosurgery without pain-control protocol)
Number of subjects: 29
Study 21180792 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing with sonic toothbrush after exposure to acid substances
Number of subjects: 25
Study 21180792 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing with sonic toothbrush plus dentifrice after exposure to acid substances
Number of subjects: 25
Study 21180792 — intervention group
Group type: COMPARATOR
Intervention: Exposure to different acid substances (orange, cola drink, vinegar, white wine, lemon juice)
Number of subjects: 25
Study 17688080 — intervention group
Group type: EXPERIMENTAL
Intervention: Monodoks 100 mg capsule (test preparation)
Number of subjects: 24
Study 17688080 — intervention group
Group type: COMPARATOR
Intervention: 100 mg capsule of the originator product (reference preparation)
Number of subjects: 24
Study 16378560 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone triage for routine asthma care
Number of subjects: 194
Study 16378560 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic care
Number of subjects: 194
Study 12443524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physiotherapy program (manual therapy, exercise, education)
Number of subjects: 57
Study 10501820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 6.25 microg
Number of subjects: 125
Study 10501820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 12.5 microg
Number of subjects: 125
Study 10501820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 25 microg
Number of subjects: 125
Study 10501820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 50 microg
Number of subjects: 125
Study 10501820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 7852490 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy (0.04 +/- 0.01 IU/kg daily)
Number of subjects: 40
Study 7852490 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 40
Study 2045853 — intervention group
Group type: EXPERIMENTAL
Intervention: MAb DF3
Number of subjects: 190
Study 2045853 — intervention group
Group type: EXPERIMENTAL
Intervention: MAb CU18
Number of subjects: 190
Study 2045853 — intervention group
Group type: EXPERIMENTAL
Intervention: MAb F36/22
Number of subjects: 190
Study 2045853 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific antibody mentioned)
Number of subjects: 190
Study 6988941 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid antacid preparation (Link)
Number of subjects: 36
Study 6988941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30939085 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic intervention
Number of subjects: 25
Study 30939085 — intervention group
Group type: COMPARATOR
Intervention: Minimal-effect treatment
Number of subjects: 25
Study 30939085 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 25
Study 27841098 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 27841098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26093776 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives plus text message reminders
Number of subjects: 0
Study 26093776 — intervention group
Group type: COMPARATOR
Intervention: Text message reminders alone
Number of subjects: 0
Study 24029304 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT guided self-help (DBTgsh); 6 support calls over 13 weeks
Number of subjects: 60
Study 24029304 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT guided self-help (DBTgsh); assessed at 6-month follow-up
Number of subjects: 60
Study 24029304 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL) control group
Number of subjects: 60
Study 21544313 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban 30 mg
Number of subjects: 100
Study 21544313 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban 60 mg
Number of subjects: 100